Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford researchers become EMBO members

Two University of Oxford academics have become the latest to join the eminent life scientists in Europe and beyond that make up the European Molecular Biology Organization (EMBO).

Parkinson’s drug effective in treating persistent depression

A drug used for Parkinson’s disease has been shown to be effective in reducing the symptoms of difficult to treat depression, in a study led by the University of Oxford.

Construction begins on state-of-the-art research facility

The University of Oxford held a groundbreaking ceremony on Tuesday 24 June to celebrate the start of construction of the Cyrus Poonawalla Vaccines Research Building. The ceremony marks a significant milestone in Oxford’s mission to counter and constrain global health threats.

Oxford to lead new £50m MRC Centre to develop brain stimulation device-based therapies

A new Medical Research Council Centre of Research Excellence (MRC CoRE) aims to develop brain stimulation devices to treat conditions such as Parkinson’s, dementia, stroke and childhood epilepsy.

How do vaccines reduce the risk of dementia?

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory syncytial virus (RSV) is associated with a 29% reduction in dementia risk in the following 18 months. The findings suggest a novel explanation for how vaccines produce this effect.

‘Single shot’ malaria vaccine delivery system could transform global immunisation

Oxford researchers have developed programmable microcapsules to deliver vaccines in stages, potentially eliminating the need for booster shots and increasing immunisation coverage in hard-to-reach communities.

Associate Professor reaches new heights with the Thames Valley Air Ambulance

David Metcalfe, Associate Professor of Emergency Medicine at Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), has begun a two-year secondment with Thames Valley Air Ambulance.

Alan Davidson Foundation renews funding for ground-breaking motor neuron disease research at Oxford

As part of its renewed commitment, the Alan Davidson Foundation will continue to fund a full-time project manager to facilitate the ongoing coordination and growth of the ACORN study. The foundation is also contributing to the cost of a research fellow to support the next phase of the project.

Oxford academics awarded European Research Council Advanced Grants for cutting-edge research

Seven researchers at the University of Oxford, including four from Medical Sciences, have been awarded Advanced Grants from the European Research Council, each worth up to €2.5 million over a period of five years.

Identification of a new metabolic axis underpinning cardiac dysfunction in diabetes

A new publication from Department of Physiology, Anatomy and Genetics identifies a new metabolic axis which explains why the diabetic heart becomes fatty.

Oxford’s OrganOx is shortlisted for the MacRobert Award 2025

The Royal Academy of Engineering has announced the finalists for the 2025 MacRobert Award, the longest running and most prestigious prize for UK engineering innovation.

Oxford neurosurgeon secures nearly £2 million for brain cancer trial

Associate Professor Puneet Plaha of the Nuffield Department of Surgical Sciences has been awarded a £1.98 million NIHR Health Technology Assessment (HTA) grant to lead a five-year clinical trial addressing one of the most critical questions in brain cancer care.

King's Birthday Honours 2025

Professor Andrew Carr has been recognised and celebrated in the 2025 King's Birthday Honours list.

Oxford researchers uncover a potential new therapeutic target for a hard-to-treat form of leukaemia

Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.

Oxford strengthens global mindfulness research with £1 million gift

The University of Oxford has announced a £1 million donation to advance the work of the Oxford Mindfulness Research Centre.

Intensive weight loss programme improves eating disorder symptoms in people with Type 2 Diabetes at risk of eating disorders, new study finds

New study finds intensive diet programmes safely improve eating disorder symptoms in people with type 2 diabetes. Research published in The Lancet Psychiatry challenges assumptions about weight loss interventions for vulnerable patients, potentially expanding treatment options.

New consortium to make UK a world leader in AI drug discovery

A new consortium, co-led by NDM researchers, has just been announced, aiming to make the UK a leader in artificial intelligence-driven drug discovery. The ‘OpenBind’ consortium will slash the cost of drug discovery and development by as much as £100 billion.

Early-career researcher wins £1.2 million Wellcome award

Mr Keaton Jones from the Nuffield Department of Surgical Sciences has secured a prestigious Wellcome Early-Career Award worth £1.2 million. His research will investigate the role of macrophages, a type of immune cell, and their metabolism in driving immunotherapy resistance in pancreatic cancer.

New research reveals druggable target arising from chromosomal rearrangement in aggressive leukaemia

Researchers at the University of Oxford have uncovered a potential new therapeutic target in a particularly aggressive and hard-to-treat form of leukaemia.

Oxford vaccine against deadly Nipah virus granted European Medicines Agency PRIME designation

The University of Oxford’s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe’s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.

Load More